Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

#AAN2022 – Long-term Vyvgart Eases gMG Symptoms

Long-term treatment with Vyvgart (efgartigimod alfa-fcab) is safe and well tolerated, and leads to a sustained improvement in generalized myasthenia gravis (gMG) disease scores. These findings come from an interim analysis of ADAPT+ (NCT03770403), an ongoing Phase 3, open-label, three-year extension of ADAPT (NCT03669588) that is…

Rozanolixizumab May Safely Ease Symptom Severity in gMG Patients

Rozanolixizumab, UCB’s investigational antibody, may ease symptom severity in adults with generalized myasthenia gravis (MG), and help them carry on with daily activities, top-line data from the Phase 3 MycarinG study suggests. Moreover, rozanolixizumab, given as an under-the-skin (subcutaneous) infusion, was found to be generally safe and…

Soliris May Be Safe, Effective for Rituximab-refractory gMG

Soliris (eculizumab) appears to be safe and effective for patients with hard-to-treat generalized myasthenia gravis (gMG) who have acetylcholine receptor (AChR) antibodies, a study has found. Its benefits were extended to a particular group of patients from the Phase 3 REGAIN clinical trial and its extension study who were treated…

Myasthenic Crisis During Sedation Leads to Diagnosis

A recent case report describes an elderly woman who was first diagnosed with myasthenia gravis (MG) after experiencing a myasthenic crisis while being sedated for a surgical procedure. “This case reports a form of discovery of [a] myasthenic crisis outside the usual circumstance,” its authors wrote. “The prognosis depends…